Simon Krost

Simon Krost

Auto-generated profile, based on publicly available information

Simon Krost

Department of General Pediatrics, Hematology and Oncology, University Children’s Hospital Tuebingen, Tuebingen, Germany

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2024 in Leukemia
Verified
Journal Article
Open access
PDF file
DADaniel Atar
Daniel Atar
LRLara Ruoff
Lara Ruoff
AMAnna-Sophia Mast
Anna-Sophia Mast
SKSimon Krost
Simon Krost
MMMoustafa Moustafa-Oglou
Moustafa Moustafa-Oglou
CSChristian Seitz
Christian Seitz
Targeting AML by chimeric antigen receptor T-cells (CAR-T) is challenging due to the promiscuous expression of AML-associated antigens in healthy hematopoiesis and high degree of inter- and intratumoral heterogeneity. Here, we present single-cell expression data of AML-associated antigens in 30 primary pediatric AML samples. We identified CD33, CD38, CD371, IL1RAP and CD123 as the most frequently expressed. Notably, high variability was observed not only across the different patient samples but also among leukemic cells of the same patient suggesting the necessity of multiplexed targeting approaches. To address this need, we utilized our modular Adapter CAR (AdCAR) platform, enabling precise qualitative and quantitative control over CAR-T-cell function. We show highly efficient and target-specific activity for newly generated adapter molecules (AMs) against CD33, CD38, CD123, CD135 and CD371, both in vitro and in vivo. We reveal that inherent intratumoral heterogeneity in antigen expression translates into antigen escape and therapy failure to monotargeted CAR-T therapy. Further, we demonstrate in PDX models that rational combinatorial targeting by AdCAR-T-cells can cure heterogenic disease. In conclusion, we elucidate the clinical relevance of heterogeneity in antigen expression in pediatric AML and present a novel concept for precision immunotherapy by combinatorial targeting utilizing the AdCAR platform.

18 September 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
SKSimon Krost
Simon Krost
AMAnna-Sophia Mast
Anna-Sophia Mast
DADaniel Atar
Daniel Atar
BKBeate Kristmann
Beate Kristmann
SSSophia Scheuermann
Sophia Scheuermann
CSChristian M. Seitz
Christian M. Seitz
Antigen heterogeneity and antigen-negative relapse represent major limitations to durable CAR-T cell efficacy in B-lineage malignancies. We previously developed the Adapter CAR-T cell (AdCAR-T) platform, which enables flexible redirection of engineered T cells to distinct surface antigens through biotinylated adapter molecules (AMs). In this study, AMs generated from an in-house-produced tafasitamab biosimilar (anti-CD19), commercial rituximab (anti-CD20), and an in-house-produced daratumumab biosimilar (anti-CD38) mediated potent, antigen-specific AdCAR-T cell cytotoxicity. While single-antigen targeting resulted in the selection of antigen-negative tumor populations, simultaneous targeting of CD19, CD20, and CD38 effectively controlled a defined heterogeneous Burkitt lymphoma model in vitro and induced sustained tumor control in vivo . Selective loss of the CD38 + AdCAR-T cell population after CD38-directed AM exposure was consistent with fratricide; however, the surviving CD38 low population retained cytotoxic activity. These findings establish combinatorial AdCAR-T cell targeting as a flexible pan-B-lineage strategy for addressing pre-existing antigen heterogeneity and support further development of antibody-derived AM combinations for B-cell malignancies.